Losartan v atenolol in isolated systolic hypertension and left ventricular hypertrophy (LVH) at mean 4.7 years ‡
| Outcomes | Losartan | Atenolol | Adjusted RRR (95% CI)§ | Adjusted NNT |
|---|---|---|---|---|
| Composite endpoint|| | 11% | 16% | 25% (−1 to 44) | Not significant |
| Unadjusted NNT (CI) | ||||
|---|---|---|---|---|
| ‡Abbreviations defined in glossary; unadjusted NNT and CI calculated from data in article. | ||||
| §Adjusted for degree of LVH and Framingham risk score at baseline. | ||||
| ||Cardiovascular mortality, stroke, and myocardial infarction. | ||||
| Cardiovascular mortality | 4% | 8% | 46% (13 to 66) | 27 (16 to 84) |
| Stroke | 5% | 8% | 40% (8 to 62) | 28 (16 to 112) |
| All cause mortality | 10% | 14% | 28% (0 to 47) | 25 (13 to 213) |
| New onset diabetes | 6% | 9% | 38% (3 to 60) | 31 (16 to 735) |